Drug development projects
We cooperated with pharmaceutical companies in multiple drug development projects by performing structural studies of complexes of target proteins with inhibitors. Until the end of 2019 these projects were performed by a specialized laboratory – IIMCB Structural Biology Center with Marcin Nowotny as a CSO.
A published example of such cooperation concerns OATD-01 compound developed by OncoArendi Therapeutics company. OATD-01 is an inhibitor chitotriosidase/acidic mammalian chitinase which can be used in the treatment of idiopathic pulmonary fibrosis. The compound recently completed phase I clinical studies. We contributed the structural characterization of the complex between chitinase and the inhibitor.
Robert Koralewski, Barbara Dymek, Marzena Mazur, Piotr Sklepkiewicz, Sylwia Olejniczak, Wojciech Czestkowski, Krzysztof Matyszewski, Gleb Andryianau, Piotr Niedziejko, Michal Kowalski, Mariusz Gruza, Bartłomiej Borek, Karol Jedrzejczak, Agnieszka Bartoszewicz, Elżbieta Pluta, Aleksandra Rymaszewska, Magdalena Kania, Tomasz Rejczak, Sylwia Piasecka, Michal Mlacki, Marcin Mazurkiewicz, Michał Piotrowicz, Magdalena Salamon, Agnieszka Zagozdzon, Agnieszka Napiorkowska-Gromadzka, Aneta Bartlomiejczak, Witold Mozga, Paweł Dobrzański, Karolina Dzwonek, Jakub Golab, Marcin Nowotny, Jacek Olczak, and Adam Golebiowski, Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis. J Med Chem 2020 Dec 24;63(24):15527-15540. Published October 20, 2020, https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01179#
Close-up view of active site of hCHIT1 (represented as surface colored according to electrostatic potential) in complex with OATD-01 (blue sticks).